OCULAR THERAPEUTIX, INC Deferred Revenue Recognized
OCULAR THERAPEUTIX, INC (OCUL) reported Deferred Revenue Recognized of $128.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-05.
Financial Statements › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2026-02-05
- OCULAR THERAPEUTIX, INC contract with customer, liability, revenue recognized for the quarter ending 2025-03-31 was $64.00K, a 8.47% increase year-over-year.
- OCULAR THERAPEUTIX, INC contract with customer, liability, revenue recognized for the quarter ending 2024-03-31 was $59.00K, a 63.13% decline year-over-year.
- OCULAR THERAPEUTIX, INC contract with customer, liability, revenue recognized for the quarter ending 2023-03-31 was $160.00K, a 76.78% decline year-over-year.
- OCULAR THERAPEUTIX, INC contract with customer, liability, revenue recognized for the quarter ending 2022-03-31 was $689.00K.
- OCULAR THERAPEUTIX, INC contract with customer, liability, revenue recognized for fiscal 2025 was $128.00K, a 51.15% decline from fiscal 2024.
- OCULAR THERAPEUTIX, INC contract with customer, liability, revenue recognized for fiscal 2024 was $262.00K, a 54.28% decline from fiscal 2023.
- OCULAR THERAPEUTIX, INC contract with customer, liability, revenue recognized for fiscal 2023 was $573.00K, a 44.74% decline from fiscal 2022.
- OCULAR THERAPEUTIX, INC contract with customer, liability, revenue recognized for fiscal 2022 was $1.04M.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 12 month |
|---|---|---|---|---|
| 2025-12-31 | $128.00K 10-K · filed 2026-02-05 | |||
| 2025-09-30 | $128.00K 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | $128.00K 10-Q · filed 2025-08-05 | |||
| 2025-03-31 | $64.00K 10-Q · filed 2025-05-05 | |||
| 2024-12-31 | $262.00K 10-K · filed 2025-03-03 | |||
| 2024-09-30 | $200.00K 10-Q · filed 2024-11-14 | |||
| 2024-06-30 | $121.00K 10-Q · filed 2024-08-07 | |||
| 2024-03-31 | $59.00K 10-Q · filed 2024-05-07 | |||
| 2023-12-31 | $573.00K 10-K · filed 2024-03-11 | |||
| 2023-09-30 | $449.00K 10-Q · filed 2023-11-07 | |||
| 2023-06-30 | $318.00K 10-Q · filed 2023-08-07 | |||
| 2023-03-31 | $160.00K 10-Q · filed 2023-05-08 | |||
| 2022-12-31 | $1.04M 10-K · filed 2023-03-06 | |||
| 2022-09-30 | $864.00K 10-Q · filed 2022-11-07 | |||
| 2022-06-30 | $811.00K 10-Q · filed 2022-08-08 | |||
| 2022-03-31 | $689.00K 10-Q · filed 2022-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |